Special Issue "Diagnosing NAFLD: Which Tool, Where, When and Why to Use It"
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 18975
Interests: nonalcoholic fatty liver disease; metabolic syndrome; obesity; atherosclerosis and NAFLD; PCOS and NAFLD; HCV-related chronic hepatitis; HCV-related arthritis; therapy of liver cirrhosis; portal hypertension; hepatic encephalopathy; imaging ultrasonography of liver and spleen; psoriatic arthritis and NAFLD; cytokines in obesity
Special Issues, Collections and Topics in MDPI journals
Special Issue in Journal of Clinical Medicine: Should Physicians Consider NAFLD a Primary or Secondary Disease?
Special Issue in International Journal of Molecular Sciences: Thyroid Hormones and NAFLD: New Insights
Special Issue in International Journal of Molecular Sciences: Thyroid Hormones and NAFLD: New Insights 2.0
Non-alcoholic fatty liver disease (NAFLD) is an important cause of chronic liver disease, hepatocellular carcinoma, and liver transplant worldwide. Furthermore, it is associated with increased risk of heart disease, type 2 diabetes (T2DM), chronic kidney disease, and malignancies including, among others, prostate cancer. NAFLD is highly prevalent among patients with obesity and related co-morbidities, such as PCOS and OSAS. The more aggressive form of NAFLD, including non-alcoholic steatohepatitis (NASH) and advanced fibrosis, is linked to high risk for all-cause and liver-related mortality. Weight loss via lifestyle changes comprehending dietary modification and exercise is the first-line intervention used in treating and improving NAFLD/NASH.
Currently, there are no approved pharmacological interventions for NASH, but there are various ongoing trials to try to reduce the progression of this form. The rationale for these efforts consists of separating simple fatty liver from NASH. However, there are at least three schools of thought on that approach: The first one is the aforementioned. The second one emphasizes the preventive approach, thus promptly diagnosing the simple form (i.e., NAFLD). The third addresses the major causes of NAFLD/NASH (i.e., obesity (mainly abdominal) and T2DM) in the very initial phase. For this very reason, the discovery of NAFLD/NASH is of pivotal importance. Nevertheless, the skyrocketing health costs of this disease force physicians and health care providers to find simple and possibly inexpensive tools to apply, even though they do not always have complete reliability in diagnosing such diseases.
Prof. Dr. Giovanni Tarantino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Histology: Liver Biopsy
- Imaging: CT, MRI, MRE, PDFF, Ultrasound, TE, ARFI
- Surrogate markers: NAFLD ridge score, NAFLD liver Fat Score, Hepatic steatosis Index, Fatty Liver Index, Lipid accumulation product index, FLIP algoritm, CHeK score, NFS, Fib-4, APRI, BARD score, ELF, Hepascore, Fibrotest, fibroSURE/Actitest, FibroMeter NAFLD index
- Micro RNA, polymorfisms, cytokines, growth factors, hormones, genomics, transcriptomics, lipidomics, proteomics, and metabolomics